8-KOther Events

EIDP, Inc. 8-K Report (Oct 24, 2001)

Filed October 24, 2001For Securities:CTA-PBCTA-PA

Summary

EIDP, Inc. (operating as DuPont) reported third quarter 2001 earnings of $0.12 per share, excluding one-time items, a significant decrease from $0.51 per share in the prior year's quarter. This decline is attributed to the challenging macroeconomic environment, particularly the recession in U.S. manufacturing, leading to lower sales volumes and margin pressures across most segments. The company also announced the completion of its sale of DuPont Pharmaceuticals to Bristol-Myers Squibb for $7.8 billion on October 1, 2001, a strategic move expected to contribute approximately $4 billion in after-tax gain in the fourth quarter. Despite the difficult operating conditions, DuPont emphasized its financial strength and continued investment in future growth. Segment sales decreased by 14% year-over-year, with notable volume declines in the U.S. and Asia Pacific regions. The company is actively managing costs and expects fourth quarter earnings per share to be roughly similar to the third quarter, factoring in continued economic uncertainty, particularly following the September 11th events, alongside potential benefits from lower raw material costs and restructuring programs.

Key Highlights

  • 1Third quarter 2001 earnings per share (excluding one-time items) were $0.12, down significantly from $0.51 in the prior year.
  • 2Total segment sales for the third quarter were $6.4 billion, a 14% decrease compared to the third quarter of 2000, primarily due to lower volumes and prices.
  • 3The company completed the sale of its Pharmaceuticals business to Bristol-Myers Squibb for $7.8 billion on October 1, 2001.
  • 4Lower volumes, particularly in U.S. manufacturing and Asia Pacific, and margin pressure were key drivers of the earnings decline.
  • 5The company anticipates fourth quarter 2001 earnings per share to be roughly similar to the third quarter, with ongoing economic uncertainties.
  • 6The report details significant one-time items, including a reserve for the Monsanto YieldGard settlement and benefits from tax changes related to the Pharmaceuticals sale.
  • 7CEO Charles O. Holliday Jr. noted the challenging business environment but expressed confidence in DuPont's financial strength and ability to invest in the future.

Frequently Asked Questions

DuPont reported earnings of $0.12 per share (excluding one-time items) for the third quarter of 2001, a substantial decrease from $0.51 per share in the same quarter of 2000. Consolidated sales were $5.6 billion, down from $6.4 billion in the prior year's quarter. Segment sales declined by 14% to $6.4 billion, primarily due to lower volumes and pricing.

The primary reason for the earnings decline was the challenging macroeconomic environment, specifically the ongoing recession in U.S. manufacturing, which led to significantly lower sales volumes and downward pressure on profit margins across most of DuPont's business segments. Adverse currency effects also played a role.

On October 1, 2001, DuPont completed the sale of its Pharmaceuticals business to Bristol-Myers Squibb for $7.8 billion in cash. This divestiture is a significant strategic move. DuPont expects to record an after-tax gain of approximately $4 billion from this transaction in its fourth quarter results.

DuPont expects fourth quarter earnings per share to be roughly similar to the third quarter. This outlook considers continued economic deterioration offsetting seasonal gains, further pricing pressure, and lower Pharmaceutical segment earnings, balanced by potential benefits from lower raw material costs, increased cost savings from restructuring, and lower interest expenses.